Analysts have been eager to weigh in on the Healthcare sector with new ratings on EDAP TMS (EDAP), Heat Biologics (HTBX) and United Therapeutics (UTHR).
EDAP TMS (EDAP)
H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on EDAP TMS today and set a price target of $6.50. The company’s shares closed yesterday at $2.34, close to its 52-week low of $2.07.
According to TipRanks.com, Ramakanth is a 1-star analyst with an average return of -0.7% and a 34.4% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, IntelGenx Technologies, and Leap Therapeutics Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for EDAP TMS with a $6.50 average price target.
See today’s analyst top recommended stocks >>
Heat Biologics (HTBX)
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Heat Biologics today and set a price target of $6. The company’s shares closed yesterday at $1.65, close to its 52-week low of $1.09.
Pantginis said:
“Valuation and risks to price target achievement. We reiterate our Buy rating and $6 price target. Our price target is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Our valuation is currently based solely on the HS-110 opportunity in NSCLC, and only on the U.S. market based on what we consider to be modest penetration rates.”
According to TipRanks.com, Pantginis has 0 stars on 0-5 star ranking scale with an average return of -17.7% and a 26.6% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Checkpoint Therapeutics Inc, and Strata Skin Sciences Inc.
Heat Biologics has an analyst consensus of Hold.
United Therapeutics (UTHR)
In a report released today, Andrew Fein from H.C. Wainwright reiterated a Hold rating on United Therapeutics, with a price target of $95. The company’s shares closed yesterday at $116.31.
Fein observed:
“Our price target of $95/share is based on an equally weighted composite of: (a) $98/ share, as a 35x multiple of taxed and diluted FY22 GAAP EPS of $5.78 discounted back to and (b) an NPV of $92/share, discount rate 12.5%, growth rate -2%.”
According to TipRanks.com, Fein is a 4-star analyst with an average return of 8.6% and a 42.8% success rate. Fein covers the Healthcare sector, focusing on stocks such as Proteostasis Therapeutics Inc, ACADIA Pharmaceuticals Inc, and Strongbridge Biopharma Plc.
United Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $142.40, representing a 22.4% upside. In a report released yesterday, Cowen & Co. also maintained a Hold rating on the stock with a $106 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on UTHR:
